Aflibercept para degeneración macular asociada a la edad y oclusión de la vena central de la retina [Aflibercept for age-related macular degeneration and central retinal vein occlusion]


Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
To assess the available evidence on the efficacy, safety and coverage policy related aspects on the use of aflibercept in patients with age-related macular degeneration and central retinal artery thrombosis.

Authors' conclusions
The evidence found for wet AMD was of very high methodological quality. All the aflibercept doses and schemes evaluated were as effective as ranibizumab (standard treatment) for the treatment of wet AMD patients. No evidence was found supporting aflibercept in patients with central retinal vein occlusion.

Final publication URL

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Antibodies, Monoclonal, Humanized; Macular Degeneration; Retinal Vein Occlusion

Language Published
Spanish

Country of organisation
Argentina

English summary
An English language summary is available.

Address for correspondence
Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar

AccessionNumber
32014000267

Date abstract record published
28/01/2014